Notably, our combination therapy effectively counteracts the immunosuppressive TME by reducing M-MDSC and Treg infiltration, which are known to promote tumor progression through secreting inhibitory cytokines (IL-6, IL-10, and TGF-β) [53,54]. This evidence concerns the gene IL6 and neoplasm.